The independent medical news service

Trastuzumab deruxtecan achieves durable responses in individuals who have received prior treatment for metastatic non-small-cell lung cancer harboring HER2 mutations, suggests the DESTINY-Lung01 trial.

Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.

Click through to read more about this approval

The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.

Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.

Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.

Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.

The ATLANTIS trial has found no significant overall survival improvement with the combination of lurbinectedin and doxorubicin versus chemotherapy in previously treated patients with small-cell lung cancer.

The addition of durvalumab plus tremelimumab to chemotherapy significantly improves the outcomes of people with untreated metastatic non-small-cell lung cancer, shows the POSEIDON trial.

Stereotactic ablative body radiotherapy offers similar outcomes, in terms of toxicity and efficacy, whether it is given as a single fraction or in multiple fractions to patients with up to three lung oligometastases, SAFRON II trial data show.

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

Antibiotic use does not impair the survival of patients with metastatic non-small-cell lung cancer treated with first-line chemoimmunotherapy, suggest results from an international retrospective study.

Hypofractionated image-guided radiotherapy does not improve survival relative to conventional radiotherapy in patients with stage II or III non-small-cell lung cancer ineligible for concurrent chemoradiotherapy, research shows.

Study findings suggest that using a genomic-adjusted radiation dose may help overcome the heterogeneity of tumor response to radiotherapy and improve overall survival for patients with cancer.

The seropositivity rate in response to the Pfizer–BioNTech (BNT162b2) vaccine against SARS-CoV-2 remains high around 4 months after the second dose in cancer patients undergoing active therapy, report Israeli researchers.

Nondiabetic patients with stage III non-small-cell lung cancer do not benefit from the addition of metformin to chemoradiotherapy, suggest results from two phase 2 trials.

The addition of ipilimumab to nivolumab does not improve the survival outcomes of patients with advanced squamous non-small-cell cancer who have previously received chemotherapy, shows the phase 3 LUNG-MAP S1400I trial.

Smokers who quit after receiving a diagnosis of early-stage non-small-cell lung cancer significantly improve their likelihood of survival relative to those who continue smoking, shows a large prospective cohort study.

Phase 2 study results indicate that savolitinib has promising antitumor activity in Chinese patients with non-small-cell lung cancer harboring MET exon 14 skipping alterations, including those with pulmonary sarcomatoid carcinoma.

Adding perioperative durvalumab to neoadjuvant chemotherapy could be a feasible option for patients with resectable, locally advanced non-small-cell lung cancer with mediastinal lymph node involvement, suggest phase 2 trial data.